Matricis.ai Launches First U.S. Clinical Pilot of EndomAI for AI-Assisted Detection of Endometriosis with SimonMed

Collaboration marks the first clinical pilot of AI-assisted MRI analysis for endometriosis.

Matricis.ai, a healthcare technology company developing artificial intelligence solutions for gynecological imaging in a global women’s imaging market estimated at more than $5.2 billion, announced a clinical collaboration with SimonMed Imaging, one of the largest outpatient imaging providers in the United States. The partnership launches the first U.S. clinical pilot of EndomAI, Matricis.ai’s flagship AI platform designed to assist radiologists in detecting endometriosis from MRI scans. The pilot comes at a pivotal moment for the field, as recent ACOG clinical guidelines recognize MRI as a key tool in the endometriosis clinical pathway. The pilot also expands the company’s technological advantage built on one of the world’s largest proprietary annotated datasets in gynecological imaging.

Endometriosis is a condition that affects 1 in 10 women of reproductive age worldwide. It is a complex disease that is frequently underdiagnosed despite affecting millions of women. As a result, patients often experience long delays between the onset of symptoms and a confirmed diagnosis. Studies suggest that the average time from symptom onset to diagnosis ranges from 7-10 years, with nearly 42% of women reporting that their pain was initially dismissed as “normal.” Additionally, 30-50% of women with endometriosis experience fertility challenges, underscoring the need for earlier and more reliable detection.

Also Read: AiThority Interview with Glenn Jocher, Founder & CEO, Ultralytics

EndomAI aims to address these diagnostic challenges by:

• Generating standardized reporting templates and structured outputs,
• Mapping the distribution and extent of lesions, aiding in surgery planning,
• Providing decision support for follow-up care and specialist referrals.

In the initial pilot phase, patients with suspected or diagnosed endometriosis will undergo an MRI scan at select SimonMed centers. The study will evaluate the impact of AI-assisted reporting on diagnostic consistency, lesion detection, and radiologist confidence when communicating findings to referring OB/GYN physicians. All imaging interpretations will remain under the supervision of SimonMed’s board-certified radiologists.

“A decade-long diagnostic delay for endometriosis is unacceptable in modern medicine, and AI has the potential to change that,” said Raphaelle Taub, CEO and co-founder of Matricis.ai. “The latest ACOG guidelines, recognizing MRI as a key tool for characterizing endometriosis, mark an important turning point for the field. Our collaboration with SimonMed allows us to bring AI directly into clinical radiology workflows and accelerate the adoption of advanced imaging in women’s health.”

“March, Endometriosis Awareness Month, is an important reminder that 200 million of women still face years of uncertainty before receiving a diagnosis,” said Taub. “Improving the clarity and consistency of imaging interpretation can help clinicians identify the disease earlier and give patients a clearer role in treatment decisions.”

“Endometriosis is a highly variable disease that often takes up to a decade to diagnose,” said Dr. Sean Raj, Chief Medical Officer and Chief Innovation Officer of SimonMed. “With AI-supported MRI technologies like EndomAI, we hope to reduce that diagnostic time and increase confidence in image interpretation, all while providing referring physicians with clearer information for treatment planning.”

By partnering with one of the largest imaging networks in the United States, Matricis.ai aims to accelerate the clinical validation and deployment of AI tools designed to support radiologists and gynecologists in diagnosing complex gynecological diseases.

This clinical pilot represents a key milestone in the clinical validation and commercial deployment of our technology,” added Taub. “It validates our technology in one of the largest imaging networks in the United States and positions us to accelerate regulatory approval and commercial deployment.”

Also Read: ​​The Infrastructure War Behind the AI Boom

[To share your insights with us, please write to psen@itechseries.com]